{
    "nctId": "NCT04985058",
    "briefTitle": "Real-world Data in Patients With Breast Cancer Treated With Abemaciclib",
    "officialTitle": "Real-world Clinical Outcome and Toxicity Data in Patients With Breast Cancer Treated With Abemaciclib Combined With Endocrine Therapy: the Experience of the Hellenic Cooperative Oncology Group",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 108,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed HR-positive, HER2-negative breast cancer\n* Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology\n* 18 years or older\n* Any menopausal status\n* Treatment with abemaciclib in combination with endocrine therapy\n* Any endocrine therapy\n* At least two months of treatment with abemaciclib",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}